Ovarian cancer market set to smash $6.7 billion by 2025
pharmafile | October 28, 2019 | News story | Sales and Marketing | Cancer, GlobalData, ovarian cancer, pharma
New research from GlobalData has forecast that the worldwide market for ovarian cancer is set to expand at a compound annual growth rate (CAGR) of 14.4% from its 2018 valuation of $1.8 billion to reach $6.7 billion by 2028.
This growth is predicted to be driven predominantly by adoption of maintenance therapy for the disease across the US, UK, France, Germany, Spain, Italy and Japan. Alongside this, uptake of poly ADP-ribose polymerase (PARP) inhibitors in the fist-line setting and increased screening rates for genetic markers are also expected to be key drivers, according to the report Ovarian Cancer: Opportunity Analysis and Forecasts to 2028.
With regards to PARP inhibitors, three such drugs are anticipated to generate 40% of the global market in this disease – $2.8 billion – by 2028. Immune checkpoint inhibitor drugs are also expected to contribute around $1.4 billion, with five such therapies poised to enter the market.
However, new generic and biosimilar medicines for key therapies in the space such as Lynparza and Avastin are expected to negatively impact this growth in the market.
“The dramatic growth in the ovarian cancer market is largely attributed to the label expansions for PARP inhibitors such as Lynparza, Zejula and Rubraca,” explained Ufuk Ezer, Oncology and Hematology Analyst at GlobalData. “The increase in screening rates for genetic markers such as BRCA mutations and other homologous recombination deficiencies (HRDs) will enable better patient segmentation and are expected to further drive the use of PARP inhibitors.
“Combining maintenance treatment with PARP inhibitors is regarded as a major step forward in extending the lives of ovarian cancer patients. Through 2028, PARP inhibitors will occupy more space in the first-line treatment setting. In addition to Lynparza’s label expansion that was granted in 2018, Zejula, Rubraca and Abbvie’s new PARP inhibitor veliparib will also appear in the first line setting. Moreover, launches of immune checkpoint inhibitors Tecentriq, dostarlimab, Opdivo, Imfinzi and Keytruda will help transform the treatment landscape that has been stagnant in previous decades.
“Despite advancements in the treatment of newly-diagnosed ovarian cancer patients, one of the largest unmet needs, the need for effective treatment options for the relapsed platinum-resistant patients, will remain unaddressed, He continued. “In addition, the unmet need for early-stage diagnostic biomarkers and specialized treatment options for rare histological subtypes of ovarian cancer will also remain, which will provide further opportunities for diagnostics companies and drug developers.”
Matt Fellows
Related Content
Pharma&’s ovarian cancer therapy approved for use by NHS Scotland
Pharma& has announced that its treatment for ovarian cancer, Rubraca (rucaparib), has been accepted by …
LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …
Central nervous system cancer metastases – the evolution of diagnostics and treatment
The current forms of immunotherapy, how T cell therapy works and what the future holds
